Equity Overview
Price & Market Data
Price: $22.96
Daily Change: -$0.66 / 2.87%
Daily Range: $22.26 - $23.85
Market Cap: $2,585,938,688
Daily Volume: 575,203
Performance Metrics
1 Week: 5.27%
1 Month: 6.10%
3 Months: 21.35%
6 Months: 9.07%
1 Year: 44.04%
YTD: -10.66%
Company Details
Employees: 68
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.